Chargement en cours...
Moderate Renal Impairment Does Not Impact the Ability of CSL112 (Apolipoprotein A‐I [Human]) to Enhance Cholesterol Efflux Capacity
CSL112 (apolipoprotein A‐I [human]) is a novel intravenous formulation of plasma‐derived apolipoprotein A‐I (apoA‐I) that enhances cholesterol efflux capacity. Renal impairment is a common comorbidity in acute myocardial infarction patients and is associated with impaired lipid metabolism. The aim o...
Enregistré dans:
| Publié dans: | J Clin Pharmacol |
|---|---|
| Auteurs principaux: | , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
John Wiley and Sons Inc.
2018
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6587782/ https://ncbi.nlm.nih.gov/pubmed/30452776 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.1337 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|